Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Chem Biol Drug Des. 2021 Apr;97(4):997-1015. doi: 10.1111/cbdd.13824. Epub 2021 Feb 18.
According to global statistics, cancer is the second leading cause of death worldwide. Because of the heterogeneity of cancer, single-drug therapy has many limitations due to low efficacy. Therefore, combination therapy with two or more therapeutic agents is being arisen. One of the most important approaches in cancer therapy is the shot down of key genes involved in apoptotic processes and cell cycle. In this regard, siRNA is a good candidate, a highly attractive method to suppressing tumor growth and invasion. Combination therapy with siRNAs and chemotherapeutic agents can overcome the multidrug resistance and increase apoptosis. The efficient delivery of siRNA to the target cell/tissue/organ has been a challenge. To overcome these challenges, the presence of suitable delivery systems by using nanoparticles is interesting. In this review, we discuss the current challenges for successful RNA interference. Also, we suggested proper a strategy for delivering siRNA that can be useful in targeting therapy. Finally, the combination of a variety of anticancer drugs and siRNA through acceptable delivery systems and their effects on cell cycle and apoptosis will be evaluated.
根据全球统计数据，癌症是全球第二大致死原因。由于癌症的异质性，单一药物治疗由于疗效低而存在许多局限性。因此，正在出现两种或多种治疗剂的联合治疗。癌症治疗中最重要的方法之一是下调参与细胞凋亡过程和细胞周期的关键基因。在这方面，siRNA 是一种很好的候选物，是抑制肿瘤生长和侵袭的极具吸引力的方法。siRNA 与化疗药物联合治疗可以克服多药耐药性并增加细胞凋亡。将 siRNA 有效递送到靶细胞/组织/器官一直是一个挑战。为了克服这些挑战，使用纳米颗粒的合适递药系统的出现很有意义。在这篇综述中，我们讨论了成功进行 RNA 干扰的当前挑战。此外，我们提出了一种用于递送 siRNA 的合理策略，该策略可用于靶向治疗。最后，将通过可接受的递药系统评估各种抗癌药物和 siRNA 的组合及其对细胞周期和凋亡的影响。
